The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer

Summary, in English

Abstract

Background:

Current prognostic molecular markers for epithelial ovarian cancer (EOC) are

insufficient. The aim of the current study was to investigate the role of Sox11 in EOC

Methods:

Using an in silico transcriptomic screen Sox11 was identified as a potential EOC

biomarker. Sox11 protein expression was evaluated using immunohistochemistry (IHC)

in 76 EOC cases, which were analyzed using automated algorithms to develop a

quantitative scoring model.

Results:

Sox11 mRNA expression was up-regulated in EOC compared to normal tissues.

Automated analysis of Sox11 in the EOC cohort revealed high expression of Sox11, in

40% of tumours, who had an improved recurrence free survival (RFS) (p= 0.002).

Multivariate analysis confirmed Sox11 was an independent predictor of improved RFS

after controlling for stage and grade.

Conclusions:

These data suggest that Sox11 is a new prognostic marker in EOC. Loss of SOX 11 is

associated with a decreased RFS and a more aggressive phenotype.

• Author: Donal Brennan; Sara Ek; Emma Doyle; Thomas Drew; Michael Foley; Grainne Flannelly; Darren P O´Conner; William M Gallagher; Sami Kilpinen; Olli-Pekka Kallioniemi; Karin Jirström; Colm O'Herlihy; Carl Borrebaeck
• Department/s: Department of Immunotechnology; Therapeutic pathology
• Publishing year: 2009
• Language: English
• Pages: 1510-1517
• Publication/Series: European Journal of Cancer
• Volume: 45
• Issue: 8
• Links: http://dx.doi.org/10.1016/j.ejca.2009.01.028
• Document type: Journal article
• Publisher: Elsevier
• Topic: Immunology in the medical area
• Status: Published
• ISBN/ISSN/Other: ISSN: 1879-0852